EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of Combined Treatment With Selective Androgen and Estrogen Receptor Modulators Ostarine and Raloxifen on Bone Tissue In Ovariectomized Rats

Daniel B Hoffmann, Marius Staub, Kai O Böker, Arndt F Schilling, Paul J Roch, Wolfgang Lehmann, Stefan Taudien, Swantje Oberthür, Stephan Sehmisch, Marina Komrakova

Calcified Tissue International · 2025

DOI: 10.1007/s00223-025-01431-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Calcified Tissue International, 2025. Verfasst von Daniel B Hoffmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Trauma, Orthopaedic- and Plastic Surgery, Georg-August-University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany. da…. Hauptthemen laut MEDLINE: Selective Estrogen Receptor Modulators, Raloxifene Hydrochloride, Bone and Bones, Osteoporosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Georg-August-Universität Göttingen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hormone replacement therapy in women usually focuses on estrogen and progesterone replacement. But also androgens decrease with age in women. Decrease of estrogen or androgens levels are associated with bone loss, while steroid hormone therapy often leads to negative side effects. A possible solution could be the use of selective receptor modulators (SRMs). Here, a combined treatment with a selective estrogen receptor modulator (raloxifene, RAL) and a selective androgen receptor modulator (ostarine, OST) was investigated in ovariectomized rats. The study was performed using 3-month-old female Sprague–Dawley rats. Fifteen control rats were not ovariectomized (NON-OVX). Sixty rats were ovariectomized and divided into 4 groups (n = 15/group): (1) untreated rats (OVX), (2) rats receiving OST (0.55 ± 0.08 mg/kg body weight [BW]), (3) rats receiving RAL (11.07 ± 1.77 mg/kg BW), (4) rats treated with OST and RAL. The compounds were administered orally as osteoporosis prophylaxis immediately after ovariectomy for up to 13 weeks. Thereafter, the lumbar vertebrae and femora were analyzed. OST + RAL treatment showed a favorable effect on structural and biomechanical bone parameters, demonstrating some advantages over RAL alone. RAL confirmed its antiresorptive effect on bone tissue without causing negative systemic effects. OST alone was less effective in protecting bone tissue. It increased osteoblast number, serum phosphorus, bone magnesium, and inner organ and uterus weight. The adverse effect of OST on bone magnesium level was attenuated when combined with RAL. Conversely, the combined treatment increased serum phosphorus and luteinizing hormone levels, decreased serum magnesium and calcium, and did not attenuate the organ and uterus weight increase observed after OST, raising safety concerns. These findings highlight the need for cautious evaluation of combination therapies and suggest that there is a need for alternative compounds with improved safety profiles for future osteoporosis treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Estrogen Receptor ModulatorsRaloxifene HydrochlorideBone and BonesOsteoporosisAnimalsFemaleOvariectomyRats, Sprague-DawleyRatsBone DensityDrug Therapy, CombinationAnilides

Stichwörter der Autor:innen

OstarineOsteoporosisOvariectomized rat modelRaloxifenSARMSERM

Substanzen

Selective Estrogen Receptor ModulatorsRaloxifene HydrochlorideostarineAnilides

Autor:innen und Institutionen

  • Department of Trauma, Orthopaedic- and Plastic Surgery, Georg-August-University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany. daniel.hoffmann@med.uni-goettingen.de.
  • Department of Trauma, Orthopaedic- and Plastic Surgery, Georg-August-University of Goettingen, Robert Koch St. No. 40, 37075, Goettingen, Germany.
  • Department of Medical Microbiology, Subdivision of General Hygiene and Environmental Health, University of Goettingen, Humboldallee 34a, 37073, Goettingen, Germany.
  • Department of Trauma Surgery, Hannover Medical School, University of Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Georg-August-Universität Göttingen

Zitieren

APA

Hoffmann, D. B., Staub, M., Böker, K. O., Schilling, A. F., Roch, P. J., Lehmann, W., Taudien, S., Oberthür, S., Sehmisch, S., & Komrakova, M. (2025). Effects of Combined Treatment With Selective Androgen and Estrogen Receptor Modulators Ostarine and Raloxifen on Bone Tissue In Ovariectomized Rats. Calcified Tissue International. https://doi.org/10.1007/s00223-025-01431-4

Vancouver

Hoffmann DB, Staub M, Böker KO, Schilling AF, Roch PJ, Lehmann W, et al. Effects of Combined Treatment With Selective Androgen and Estrogen Receptor Modulators Ostarine and Raloxifen on Bone Tissue In Ovariectomized Rats. Calcified Tissue International. 2025. doi:10.1007/s00223-025-01431-4

BibTeX
@article{Hoffmann2025,
  author = {Hoffmann, Daniel B and Staub, Marius and Böker, Kai O and Schilling, Arndt F and Roch, Paul J and Lehmann, Wolfgang and Taudien, Stefan and Oberthür, Swantje and Sehmisch, Stephan and Komrakova, Marina},
  title = {Effects of Combined Treatment With Selective Androgen and Estrogen Receptor Modulators Ostarine and Raloxifen on Bone Tissue In Ovariectomized Rats},
  journal = {Calcified Tissue International},
  year = {2025},
  doi = {10.1007/s00223-025-01431-4}
}
Kostenlos starten →